Peptide · Healing & recovery
TB-500 is a synthetic fragment of Thymosin Beta-4, studied for tissue repair, wound healing, and endothelial function.
TB-500 is a synthetic fragment of Thymosin Beta-4, studied for tissue repair, wound healing, and endothelial function.
TB-500 is a synthetic version of a 17-amino-acid fragment of thymosin beta-4 (the active LKKTETQ region). Thymosin beta-4 is a naturally occurring protein involved in actin sequestration and remodeling. The peptide promotes cell migration (key to wound healing), upregulates VEGF and other pro-angiogenic factors, and modulates inflammatory cytokine signaling. The actin-binding mechanism is the dominant explanation for tissue-repair effects.
Preclinical animal models and limited human data.
Not FDA-approved. Restricted on the FDA bulk substances list.
Common research and clinical-use protocols:
Dosing in research and clinical-use contexts varies. Specific protocols should always be set by a prescribing clinician, not by patient-direct sources.
Reported side effects are mild and similar to BPC-157: injection-site irritation, mild lethargy in the first week. Pre-clinical safety data is reasonable; human safety data is limited. Like BPC-157, TB-500 is on the FDA 503A bulk substances restricted list.
The standard healing stack is BPC-157 + TB-500. Some protocols add GHK-Cu for additional tissue-repair signaling, or pair with growth-hormone secretagogues (ipamorelin/CJC-1295) for systemic recovery.
Most peptides discussed on this page are compounded products requiring a prescription from a licensed clinician. Reputable telehealth peptide programs include physician-led oversight, accredited compounding pharmacies, and clear regulatory framing. For weight-management GLP-1 programs, see our provider reviews.
TB-500 is a synthetic fragment of Thymosin Beta-4, studied for tissue repair, wound healing, and endothelial function.
Not FDA-approved. Restricted on the FDA bulk substances list.
Uses include: Soft-tissue healing (research), Endothelial repair (research), Anti-inflammatory effects (research). This is research and clinical-use context, not a recommendation. Always work with a licensed clinician.
Preclinical animal models and limited human data.
Reported dosing: 2 mg subcutaneous twice weekly (research context). Actual dosing should always be determined by your prescribing clinician, not by online sources.
Yes. The World Anti-Doping Agency (WADA) lists thymosin beta-4 and its analogs as prohibited substances. Athletes subject to WADA testing should not use TB-500.
Thymosin beta-4 (the source of TB-500) is involved in tissue repair and cell migration. Thymosin alpha-1 (a different peptide) is involved in immune function. They are not interchangeable.